CURE-IBS-DNCT07238790
Use of A Complex Gut Bacterial Consortium (MITI 001) for the Treatment of Irritable Bowel Syndrome With Diarrhea
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 2 versions: 2 with changes below. See every version on ClinicalTrials.gov ↗
Notable Recruitment opened Show 5 more changesShow less
- Eligibility criteria shortened, about 44 words
- Start date changed from estimate of Dec 2025 to Mar 10, 2026
- Secondary endpoints: details revised at 2 of 2 entries
- Study description shortened, about 8 words
- Site details revised at 2 of 2 sites
- Study First Submitted
- Notable: the plan changed
Endpoints
Primary
Determine the safety of MITI-001 in the participant population
Timeframe: up to 90 days
Secondary (2)
Assess the ability of MITI-001 to restore microbial metabolic function: secondary bile acid metabolism and hydrogen consumption
Adequate relief of IBS-D symptoms
Arms and interventions
Intervention arm (MITI-001)Experimental
Dosed with MITI-001
Drugs: MITI-001 administration
Sites
2 sites in 1 country